## Edgar Filing: Regulus Therapeutics Inc. - Form 4

•	erapeutics Inc.											
Form 4	2014											
February 05 FORN Check th if no lon subject to Section Form 4 Form 5	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5					
obligation may con <i>See</i> Instr 1(b).	ons Section 17( ruction	a) of the l	Public U	tility Hol		iny A	ct of 1	Act of 1934, 935 or Section				
1. Name and Address of Reporting Person <u>*</u> Sanofi			2. Issuer Name <b>and</b> Ticker or Trading Symbol Regulus Therapeutics Inc. [RGLS]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 54 RUE LA BOETIE			<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>02/04/2014</li></ul>					DirectorX10% Owner Officer (give title Other (specify below)below)				
(Street) PARIS, I0 75008			Filed(Month/Day/Year) Applicable Line) _X_Form filed byForm filed byForm filed by					Applicable Line) X_ Form filed by Or	oint/Group Filing(Check One Reporting Person More than One Reporting			
							Р	Person				
(City)	(State)	(Zip)	Tab	le I - Non-J	Derivative Sec	urities	s Acqui	red, Disposed of,	or Beneficiall	y Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	4. Securities A order Disposed of (Instr. 3, 4 and Amount	f (D)	ed (A) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common stock, \$ 0.001 par value-	02/04/2014			Р	1,303,780	А	\$ 7.67	5,053,779	I	See footnote (1)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Regulus Therapeutics Inc. - Form 4

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transacti	5. onNumber	6. Date Exer Expiration D		7. Titl Amou		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/ e		Under Secur	rlying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh	nips	
I B	Director	10% Owner	Officer	Other
Sanofi 54 RUE LA BOETIE PARIS, I0 75008		Х		
Signatures				
	n	~ *		

/s/ John Felitti Associate Vice President Corporate Law, Financial & Securities Law

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Shares are held directly by Aventis Holdings Inc. an indirectly wholly owned subsidiary of Sanofi. Accordingly, Sanofi can be deemed to (1) share voting and dispositive power over the shares held directly by Aventis Holdings Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

02/05/2014 Date